loading
Schlusskurs vom Vortag:
$8.16
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$564.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.04M
KGV:
0.00
EPS:
-1.58
Netto-Cashflow:
$-27.38M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$8.345

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
Firmenname
Regulus Therapeutics Inc
Name
Telefon
858-202-6300
Name
Adresse
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
Mitarbeiter
34
Name
Twitter
@regulusrx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
RGLS's Discussions on Twitter

Vergleichen Sie RGLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RGLS
Regulus Therapeutics Inc
0.00 564.26M 0 -30.04M -27.38M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-27 Hochstufung Wells Fargo Equal Weight → Overweight
2024-08-02 Eingeleitet Oppenheimer Outperform
2024-03-18 Eingeleitet Leerink Partners Outperform
2018-03-28 Eingeleitet B. Riley FBR, Inc. Neutral
2018-01-05 Eingeleitet Leerink Partners Outperform
2017-06-13 Bestätigt Chardan Capital Markets Buy
2017-03-06 Bestätigt Wedbush Outperform
2017-01-30 Herabstufung Needham Buy → Hold
2017-01-30 Herabstufung Wells Fargo Outperform → Market Perform
2016-12-07 Bestätigt Chardan Capital Markets Buy
2016-11-02 Bestätigt Needham Buy
2016-07-25 Bestätigt Chardan Capital Markets Buy
2016-06-28 Bestätigt Chardan Capital Markets Buy
2016-06-28 Bestätigt FBR Capital Outperform
2016-06-28 Bestätigt Needham Buy
2016-06-07 Bestätigt Chardan Capital Markets Buy
2016-04-13 Eingeleitet Chardan Capital Markets Buy
2015-12-04 Eingeleitet Wells Fargo Outperform
2015-06-09 Eingeleitet Guggenheim Buy
2015-04-21 Fortgesetzt FBR Capital Outperform
2014-11-24 Eingeleitet Deutsche Bank Buy
2014-08-07 Bestätigt FBR Capital Outperform
2013-08-14 Bestätigt Needham Buy
Alle ansehen

Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten

pulisher
Jun 05, 2025

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 01, 2025

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.

Jun 01, 2025
pulisher
May 28, 2025

Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma

May 28, 2025
pulisher
May 28, 2025

Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues

May 28, 2025
pulisher
May 27, 2025

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News

May 27, 2025
pulisher
May 27, 2025

Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Novartis Launches Tender Offer for Regulus Therapeutics Takeover - MarketScreener

May 27, 2025
pulisher
May 25, 2025

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha

May 25, 2025
pulisher
May 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView

May 15, 2025
pulisher
May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView

May 15, 2025
pulisher
May 15, 2025

Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media

May 15, 2025
pulisher
May 14, 2025

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail

May 14, 2025
pulisher
May 14, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World

May 14, 2025
pulisher
May 10, 2025

Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World

May 10, 2025
pulisher
May 09, 2025

Regulus Therapeutics to be Acquired by Novartis - TipRanks

May 09, 2025
pulisher
May 08, 2025

Regulus: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025
pulisher
May 08, 2025

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider

May 08, 2025
pulisher
May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World

May 07, 2025
pulisher
May 06, 2025

Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com

May 06, 2025
pulisher
May 05, 2025

What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World

May 05, 2025
pulisher
May 04, 2025

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire

May 04, 2025
pulisher
May 03, 2025

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus

May 03, 2025
pulisher
May 03, 2025

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN

May 03, 2025
pulisher
May 02, 2025

Taxation With Representation: Goodwin, Haynes Boone - Law360

May 02, 2025
pulisher
May 02, 2025

Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - MSN

May 02, 2025
pulisher
May 01, 2025

Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize

May 01, 2025
pulisher
May 01, 2025

Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga

May 01, 2025
pulisher
May 01, 2025

Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare

May 01, 2025
pulisher
May 01, 2025

Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN

May 01, 2025
pulisher
May 01, 2025

Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers

May 01, 2025
pulisher
May 01, 2025

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus

May 01, 2025

Finanzdaten der Regulus Therapeutics Inc-Aktie (RGLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Regulus Therapeutics Inc-Aktie (RGLS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Collier Kathryn J
Director
Jun 16 '25
Option Exercise
9.90
1,396
13,820
67,844
Klassen Preston
President & Head of R & D
Jun 03 '25
Buy
7.99
12,000
95,852
48,055
Hagan Joseph P
Chief Executive Officer
Jan 30 '25
Buy
1.09
50,000
54,260
260,808
BALTIMORE DAVID
Director
Jan 30 '25
Buy
1.06
19,610
20,787
22,169
Aker Christopher Ray
Sr. VP & General Counsel
Jan 13 '25
Sale
1.26
38,547
48,693
54,634
Aker Christopher Ray
Sr. VP & General Counsel
Jan 14 '25
Sale
1.26
5,088
6,427
49,546
Hagan Joseph P
Chief Executive Officer
Jan 13 '25
Sale
1.26
115,290
145,634
222,572
Hagan Joseph P
Chief Executive Officer
Jan 14 '25
Sale
1.26
11,764
14,860
210,808
CALSADA CRISPINA
Chief Financial Officer
Jan 13 '25
Sale
1.26
38,716
48,906
50,566
CALSADA CRISPINA
Chief Financial Officer
Jan 14 '25
Sale
1.26
5,088
6,427
45,478
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):